0.54  -0.009 (-1.64%)		05-23 09:53
Open: 0.508 High: 0.547 Volume: 44,871		Pre. Close: 0.549 Low: 0.5325 Market Cap: 6(M)

Short term
Mid term
Targets	6-month :	0.66	1-year :	0.77
Resists	First :	0.56	Second :	0.66
Pivot price	0.5
Supports	First :	0.45	Second :	0.37
MAs	MA(5) :	0.52	MA(20) :	0.48
	MA(100) :	5.22	MA(250) :	48.84
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	72.8	D(3) :	66.5
RSI	RSI(14): 43.2
52-week	High :	269.27	Low :	0.37

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ AEON ] has closed below upper band by 3.8%. Bollinger Bands are 99% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 81 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.55 - 0.55	0.55 - 0.55
Low:	0.47 - 0.48	0.48 - 0.48
Close:	0.54 - 0.55	0.55 - 0.55

AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

Wed, 21 May 2025
Aeon Biopharma Reports Positive Q1 2025 Earnings - TipRanks

Tue, 20 May 2025
AEON Biopharma Releases New Corporate Presentation - TipRanks

Mon, 19 May 2025
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025 - The Manila Times

Mon, 19 May 2025
AEON Biopharma to Present Corporate Overview at Aegis Capital Corp. 2025 Virtual Conference - Nasdaq

Mon, 19 May 2025
AEON Biopharma Unveils Next-Gen Botulinum Toxin Therapies: CEO Details Multi-Indication Pipeline - Stock Titan

Wed, 14 May 2025
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	40 (M)
Shares Float	18 (M)
Held by Insiders	36.6 (%)
Held by Institutions	23.8 (%)
Shares Short	127 (K)
Shares Short P.Month	623 (K)

EPS	-0.16
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.71
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-597.7 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.11
Qtrly Earnings Growth	0 %
Operating Cash Flow	-43 (M)
Levered Free Cash Flow	-25 (M)

PE Ratio	-3.65
PEG Ratio	0
Price to Book value	-0.78
Price to Sales	0
Price to Cash Flow	-0.5

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.